NovoCure Limited
NASDAQ:NVCRMedical - Instruments & Supplies
-$3.51 today
- Market cap
- $1.25B
- Beta
- 0.92
- P/E (TTM)
- -9.5
- EPS (TTM)
- -$1.52
Volume 1.41M
Average 1.52M
NVCR Interest Income
Income earned on cash, deposits, and investments held by the company.
NovoCure LimitedNASDAQ: NVCR
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income remains negative
Q1 FY2026 interest income was $0, compared with $7.57M a year earlier. Trailing-twelve-month interest income was $10.54M. Over 3 fiscal years it compounded at +4.7% a year.
Context
- Interest income amounted to 2.8% of revenue in FY2025, down 5.7 pp from a year earlier.
- Interest income increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly interest income holds near $0 or moves back toward the trailing-twelve-month quarterly average of $2.64M.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 18.11M USD
- Year-over-year change
- -64.5%
- 4-year CAGR
- +101.6%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.11M | -64.5% |
| FY2024 | 2024-12-31 | 51M | +10.8% |
| FY2023 | 2023-12-31 | 46.04M | +191.6% |
| FY2022 | 2022-12-31 | 15.79M | +1339.4% |
| FY2021 | 2021-12-31 | 1.1M | — |
Interest Income vs competitors
How NVCR compares with its peers on the latest reported figures
- NVCR's LTM Mar 2026 interest income of $10.54M is the highest of the 4 companies compared; the peer median is $3.05M.
- Its year-over-year change of -71.5% is the lowest of 4, against a peer median of -13.4%.
- Interest income amounts to 1.6% of revenue for NVCR, versus a peer median of 3.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.54M | -71.5% | +4.7% | 1.6% | |
| LTM Mar 2026 | $3.09M | +201.1% | — | 3.4% | |
| LTM Jun 2026 | $3.05M | -27.6% | — | 257.1% | |
| LTM Mar 2026 | $2.59M | -13.4% | +21.3% | 2.6% | |
| Peer median (excluding NVCR) | $3.05M | -13.4% | +21.3% | 3.4% | |
Competitors are the stored peer set for NVCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 535.03M | 537.84M | 509.34M | 605.22M | 655.35M |
| Cost of Revenue | 114.88M | 114.87M | 128.28M | 137.18M | 166.88M |
| Gross Profit | 420.15M | 422.97M | 381.06M | 468.04M | 488.47M |
| Gross Margin | 78.5% | 78.6% | 74.8% | 77.3% | 74.5% |
| Research & Development | 201.3M | 206.09M | 223.06M | 209.65M | 224.54M |
| Selling, General & Admin | 263.18M | 306.41M | 390.87M | 428.89M | 417.73M |
| Operating Expenses | 464.49M | 512.5M | 614.67M | 638.54M | 642.27M |
| Depreciation & Amortization | 10.25M | 10.62M | 10.97M | 11.24M | 17.2M |
| EBITDA | (38.38M) | (67.89M) | (177.45M) | (109.58M) | (119.05M) |
| EBITDA Margin | -7.2% | -12.6% | -34.8% | -18.1% | -18.2% |
| Operating Income | (44.33M) | (89.52M) | (232.87M) | (170.5M) | (153.8M) |
| Operating Margin | -8.3% | -16.6% | -45.7% | -28.2% | -23.5% |
| Interest Income | 1.1M | 15.79M | 46.04M | 51M | 18.11M |
| Interest Expense | 8.84M | 8.11M | 4.91M | 11.66M | 0 |
| Other Income / Expenses | (7.74M) | 7.68M | 41.13M | 39.33M | 17.55M |
| Income Before Tax | (52.08M) | (81.85M) | (191.74M) | (131.16M) | (136.25M) |
| Pre-Tax Margin | -9.7% | -15.2% | -37.6% | -21.7% | -20.8% |
| Income Tax Expense | 6.28M | 10.69M | 15.3M | 37.47M | (23K) |
| Net Income | (58.35M) | (92.53M) | (207.04M) | (168.63M) | (136.23M) |
| Net Margin | -10.9% | -17.2% | -40.6% | -27.9% | -20.8% |
| EPS (Basic) | (0.56) | (0.88) | (1.95) | (1.56) | (1.22) |
| EPS (Diluted) | (0.56) | (0.88) | (1.95) | (1.56) | (1.22) |
| Weighted Avg Shares | 103.43M | 104.66M | 106.39M | 107.83M | 111.47M |
| Weighted Avg Shares (Diluted) | 103.43M | 104.66M | 106.39M | 107.83M | 111.47M |
NovoCure Limited
NASDAQ:NVCR
Intrinsic Alpha fair value
Locked
Current Price
$10.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.